Pulmonary Fibrosis Treatment
Africa · 1 shared keyword
Updated
Reviewed by Vidhi Upadhyay
Africa Geographic Atrophy Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$123.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $13.8 Mn | — | — |
| 2025 (base) | $17.4 Mn | +$3.6 Mn | — |
| 2026 (forecast) | $21.9 Mn | +$4.5 Mn | +26.2% |
| 2027 (forecast) | $27.6 Mn | +$5.7 Mn | +59.3% |
| 2028 (forecast) | $34.9 Mn | +$7.2 Mn | +101% |
| 2029 (forecast) | $44.0 Mn | +$9.1 Mn | +153.7% |
| 2030 (forecast) | $55.6 Mn | +$11.5 Mn | +220.1% |
| 2031 (forecast) | $70.1 Mn | +$14.6 Mn | +304% |
| 2032 (forecast) | $88.5 Mn | +$18.4 Mn | +409.8% |
| 2033 (forecast) | $111.7 Mn | +$23.2 Mn | +543.4% |
| 2034 (forecast) | $141.0 Mn | +$29.3 Mn | +712% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $17.4 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $141.0 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 26.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug, route and end user (see all) |
| Key players | Apellis Pharmaceuticals, Astellas Pharma Inc., Roche, Novartis AG, Annexon Biosciences (see all) |
| Regulator in Africa | AMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Geographic atrophy treatments slow the advanced form of dry age-related macular degeneration that causes vision loss.
Key segments of the geographic Atrophy Treatment market include drug (Complement C3 Inhibitors, Complement C5 Inhibitors and Pipeline Therapies) and route (Intravitreal Injection).
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the geographic Atrophy Treatment market.
Longer-acting treatments, home-based care and screening in emerging markets give the geographic Atrophy Treatment market room to grow.
High costs of new treatments, specialist shortages, low awareness and limited reimbursement in some countries hold back the geographic Atrophy Treatment market.
The geographic Atrophy Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)[2], PPB (Kenya)[3], SAHPRA (South Africa)[4] and NAFDAC (Nigeria)[5]. How care is paid for in some of these countries: universal health insurance (Egypt)[6], the SHA (Kenya)[7], planned National Health Insurance (South Africa)[8] and out of pocket and the NHIA (Nigeria)[9].
[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
[2] Egyptian Drug Authority. Checked 14 Nov 2026.
[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.
[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.
[5] NAFDAC. Checked 19 Nov 2026.
[6] Universal Health Insurance Authority. Checked 14 Nov 2026.
[7] Social Health Authority. Checked 14 Nov 2026.
[8] National Department of Health. Checked 14 Nov 2026.
[9] National Health Insurance Authority (NHIA). Checked 19 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for geographic Atrophy Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.
What doctors and scientists are doing in Geographic Atrophy Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Africa · 1 shared keyword
Africa
Africa
Africa
Africa
Africa
Healthcare Services · Africa
Digital Health · Africa
Digital Health · Africa
Medical Devices · Africa
Medical Devices · Africa
Medical Devices · Africa